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Abstract
Determining the status of breast cancer surface receptors
(estrogen receptor, progesterone receptor, HER2/neu) has become
routine in the care of patients with this disease and has proven to
be helpful in guiding treatment. For this reason, breast cancer has
become a model for molecularly guided therapy in solid tumors.
Emerging data support that these receptors are associated with
risk for developing brain metastases. Additionally, once brain
metastases have occurred these receptors may also correlate with
prognosis.
The retrospective analysis presented by Nam and coworkers
[1] is consistent with prior data suggesting increased risk for
brain metastases and shortened survival in patients with brain
metastases when there is a lack of surface hormone
receptors (estrogen receptor [ER]-negative/progesterone
receptor [PR]-negative status). This study goes one step
further and attempts to correlate the outcomes of brain
metastasis with intrinsic breast cancer subtypes, using the
receptor combinations as a surrogate marker for the subtypes
defined by gene expression microarrays. There appears to be
a higher proportion of human epidermal growth factor
receptor (HER)2-positive/ER-negative and triple-negative
disease among patients with brain metastases. HER2-
positive status did not appear to increase the risk for brain
metastasis, as described in other studies [2,3]. There are
conflicting data in the literature on the significance of HER2
with regard to brain metastases in breast cancer, and several
unanswered questions remain. Does HER2 positivity affect
risk for brain metastasis? Does HER2 positivity affect survival
among breast cancer patients with brain metastases? Finally,
do these correlations with parenchymal brain metastases
extend to leptomeningeal disease (LMD)?
Regarding the first question, there are conflicting findings in
the literature on the correlation between HER2 status and the
risk for brain metastasis. HER2-positive breast cancer has
been associated with increased risk for brain metastases in
some studies [2,3], but others found no significant
association [1,4]. In considering the possibility that HER2-
positive status may increase the risk for brain metastasis,
several confounding issues must be considered in the
trastuzumab era. It has been suggested that trastuzumab
itself may be related to the increased risk for brain metastasis
[5]. However, trastuzumab has also resulted in improved
survival in HER2-positive metastatic breast cancer. Because
brain metastasis typically occurs in late breast cancer, longer
survival may be the confounding factor in HER2-positive
patients who develop brain metastases and receive
trastuzumab. Several recent studies suggested that triple-
negative breast cancer results in poorer survival than does
HER2-positive/ER-negative status in the setting of residual
disease [6,7].
The second issue concerns the prognostic value of HER2
once brain metastasis has occurred. In the era of
trastuzumab, outcomes in HER2-positive brain metastasis
appear to be more favorable, because these patients can
been treated with trastuzumab, which results in prolonged
survival. It is believed that prolonged survival in patients with
brain metastasis who are HER2 positive is a result of
improved extracranial disease control rather than a direct
effect on the brain metastases. Median survival was
significantly longer among patients who received trastuzumab
after the onset of brain metastasis in the study reported by
Nam and coworkers [1] (12.8 months versus 4.0 months).
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Although overall prognosis may be better in HER2-positive
brain metastases, the most important reason for failure of
trastuzumab to control these metastases may be the inability
of this antibody to cross the blood-brain barrier adequately
[8]. However, the trastuzumab cerebrospinal fluid/plasma
ratio appears to increase in the setting of radiation therapy
and LMD [9], with responses observed [10]. Alternatively,
could the brain metastases simply lose expression of the
HER2 receptor? Although discordance of HER2 staining
between primary and metastatic tissues has been described
for other cancers, Fuchs and coworkers [11] reported that
the overall rate of concordance in HER2 status between brain
metastases and the primary breast cancer was 97% in 29
patients evaluated. It may be necessary to analyze larger
datasets before the association between HER2, brain
metastases, and trastuzumab can be clarified.
Finally, Nam and coworkers [1] found LMD to be the factor
most associated with a poor outcome. Given the significance
of this type of metastasis, what do we know about the
correlation between receptor status and the risk and
prognosis of LMD? LMD in breast cancer is unique
compared with LMD in other solid tumor histologies, in that a
subset of patients can have relatively prolonged survival.
Does receptor status correlate with LMD in the same way as
it might for parenchymal brain metastases? There is a paucity
of data addressing this specific issue. A small retrospective
study of breast cancer patients with LMD suggested a trend
toward an increased proportion of HER2-positive/ER-
negative breast cancer among patients with LMD than among
patients without LMD [12]. This is another area in which
additional research is greatly needed.
The report by Nam and coworkers [1] adds further evidence
that a more detailed molecular classification of disease
(longitudinally in individual patients) may lead to fruitful
hypothesis-generating data, which will help us to further
dissect the molecular mechanisms involved in the metastatic
process and eventually lead to rational treatment strategies to
prevent or treat metastasis.
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